Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OMS643762 in Huntington's Disease
NCT02074410Phase 2Terminated
- Sponsor
- Omeros Corporation
- Start
- Jan 2014
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of OMS824 in Huntington's disease (HD) (4 arms), sponsored by Omeros Corporation. Primary endpoint: Assess the Safety of OMS643762 at 28 days. Started Jan 2014; status: terminated.
02
Drugs
OMS824
03
Conditions
Huntington's disease (HD)
Beyond the preview
Go deeper on NCT02074410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02074410.